Recent investigations have identified CCL11 as a promising biomarker with dual utility—firstly, by detecting neoplastic processes through its association with tumor-associated inflammation, and secondly, in monitoring therapeutic responses via inflammation resolution tracking [59]. Here, CCL11 is linked to neoplasm.